HealthQuill Articles by: HealthQuill
Israelā€™s Teva Pharmaceutical Industries, and US-basedĀ Launch Therapeutics, have joined hands to speed up the development of an experimental asthma drug.
Drugs Health Medical

Addressing India’s asthma crisis: Ensuring access to treatments for all

HQ Team May 7, 2025: It was World Asthma Day on May 6, and let us see how India has fared in the

Read More
Rats living in urban areas spread a deadly disease called Leptospirosis as they migrate within the cities, according to Tufts University researchers, who also discovered a method to test the kidneys of the mammals.
Climate Health Research

Rats in urban areas spread Leptospirosis as they migrate: Tufts study

HQ Team May 6, 2025: Rats living in urban areas spread a deadly disease called Leptospirosis as they migrate within the cities, according

Read More
Social determinants such as quality housing, education, and job opportunities can influence peopleā€™s health outcomes more than genetic influences or access to healthcare, according to a WHO report.
Climate Health Medical

Housing, education, jobs vital to health outcomes, not genes: WHO

HQ Team May 6, 2025: Social determinants such as quality housing, education, and job opportunities can influence peopleā€™s health outcomes more than genetic

Read More
In countries with low or middle incomes, physically punishing children result in poor health, lower academic performance and impaired social-emotional development, a study finds.
Health Medical Research

Physical punishment of kids leads to poor health: NYU researchers find

HQ Team May 6, 2025: In countries with low or middle incomes, physically punishing children result in poor health, lower academic performance and

Read More
Nuravax Inc. and its partner, the Institute for Molecular Medicine, have received a $3 million grant from the National Institutes of Health to advance its Alzheimerā€™s vaccine to human trials.
Drugs Health Pharma

Nuravaxā€™s Alzheimerā€™s vaccine gets $3m grant to enter human trials

HQ Team May 5, 2025: Nuravax Inc. and its partner, the Institute for Molecular Medicine, have received a $3 million grant from the

Read More
Scientists have developed a test by studying how an abnormally-shaped protein in the spinal fluid can detect 90% of Parkinsonā€™s disease in patients, even before symptoms appear.
Drugs Health Research

New Parkinsonā€™s test to detect disease even before symptoms appear

HQ Team May 5, 2025: Scientists have developed a test by studying how an abnormally-shaped protein in the spinal fluid can detect 90%

Read More
The Global Virus Network warned of an avian influenza currently circulating in the US, spreading to humans and urged enhanced surveillance, biosecurity measures and preparations for a potential human-to-human transmission.
Drugs Health Pharma

Global virologists see potential for an H5N1 pandemic, urge rapid steps

HQ Team May 5, 2025: The Global Virus Network warned of an avian influenza currently circulating in the US, spreading to humans and

Read More
UK scientists at biotech company Stablepharma have developed a tetanus-diphtheria vaccine that is completely stable at room temperature and does not need to be refrigerated or frozen.
Drugs Health Pharma

UK company starts trial on first ‘fridge-free’ tetanus-diphtheria vaccine

HQ Team May 1, 2025: UK scientists at biotech company Stablepharma Ltd. have developed a tetanus-diphtheria vaccine that is completely stable at room

Read More
Britainā€™s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer therapy, nivolumab (Opdivo), offering a quicker administration option for eligible patients than the currently available drip treatment.Ā 
Drugs Medical Pharma

UK regulator clears subcutaneous injection of Bristol Myers for cancers

HQ Team May 1, 2025: Britainā€™s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer

Read More
Switzerlandā€™s pharmaceutical company, Novartis AG,Ā  will acquire Regulus Therapeutics for about $1.7 billion to get access to a drug to treat a genetic kidney disease called autosomal dominant polycystic kidney disease.
Drugs Health Pharma

Novartis buys Regulus for $1.7b to grab genetic kidney disease drug

HQ Team April 30, 2025: Switzerlandā€™s pharmaceutical company, Novartis AG,Ā  will acquire Regulus Therapeutics for about $1.7 billion to get access to a

Read More